Physician profile
Victor E Abraham
NPI 1003848540
$4,508.47
in general payments reported to CMS, 2019-2025
31 companies · $50.65 in 2025
The $50.65 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $1,209 · 2021: $694 · 2022: $987 · 2023: $507 · 2024: $587 · 2025: $50.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.01 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,411.54 | 2019-2025 | Xtandi |
| Neotract INC. | $665.52 | 2019-2020 | |
| Janssen Biotech, INC. | $374.84 | 2019-2024 | Erleada |
| Endo Pharmaceuticals INC. | $366.59 | 2019-2024 | Xiaflex, Aveed |
| Pfizer INC. | $321.71 | 2019-2024 | |
| Urogen Pharma, INC. | $281.38 | 2021-2023 | Jelmyto |
| Boston Scientific Corporation | $252.26 | 2019-2021 | |
| 180 Medical, INC. | $82.55 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $73.28 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $72.84 | 2023 | Gemtesa |
| Coloplast Corp | $72.19 | 2020-2025 | |
| Urovant Sciences INC | $64.68 | 2022 | |
| Antares Pharma, INC. | $58.35 | 2019-2022 | |
| Angiodynamics, INC. | $50.32 | 2024 | Nanoknife |
| Zyla Life Sciences, INC. | $49.43 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $29.78 | 2019-2020 | |
| Hollister Incorporated | $27.29 | 2022 | |
| Vertical Pharmaceuticals, LLC | $24.06 | 2020 | |
| Merck Sharp & Dohme LLC | $23.54 | 2024 | Keytruda |
| Exelixis INC. | $22.78 | 2024 | Cabometyx |
| Covidien LP | $21.69 | 2020 | |
| Axonics, INC. | $20.05 | 2021 | |
| Endo USA, INC. | $19.74 | 2024 | Aveed, Xiaflex |
| Novartis Pharmaceuticals Corporation | $18.49 | 2024 | |
| Davol INC. | $17.78 | 2024 | Arista Ah Flexitip |
| Blue Earth Diagnostics | $16.57 | 2019 | |
| Procept Biorobotics Corporation | $15.70 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $15.14 | 2019 | |
| Accord Healthcare, INC. | $14.91 | 2024 | |
| Allergan, INC. | $12.22 | 2019 | |
| Dendreon Pharmaceuticals LLC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.